Medpace Holdings, Inc. MEDP
We take great care to ensure that the data presented and summarized in this overview for Medpace Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MEDP
View all-
Black Rock Inc. New York, NY2.58MShares$1.52 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$1.35 Billion0.02% of portfolio
-
Aqr Capital Management LLC Greenwich, CT1.03MShares$605 Million0.35% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT926KShares$546 Million2.66% of portfolio
-
State Street Corp Boston, MA673KShares$397 Million0.01% of portfolio
-
Mawer Investment Management Ltd. Calgary, A0647KShares$382 Million1.79% of portfolio
-
Geode Capital Management, LLC Boston, MA643KShares$379 Million0.02% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY600KShares$354 Million0.2% of portfolio
-
Baillie Gifford & CO585KShares$345 Million0.24% of portfolio
-
Invesco Ltd. Atlanta, GA537KShares$317 Million0.05% of portfolio
Latest Institutional Activity in MEDP
Top Purchases
Top Sells
About MEDP
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Insider Transactions at MEDP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2025
|
Cornelius P. Mc Carthy Iii Director |
BUY
Exercise of conversion of derivative security
|
Direct |
49
+0.47%
|
-
|
|
Dec 31
2025
|
Robert O. Kraft Director |
BUY
Exercise of conversion of derivative security
|
Direct |
56
+5.93%
|
-
|
|
Dec 31
2025
|
Brian T Carley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
62
+0.24%
|
-
|
|
Dec 05
2025
|
Susan E Burwig Exec. VP, Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+17.39%
|
$1,070,000
$107.93 P/Share
|
|
Dec 03
2025
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
668
-0.1%
|
$394,120
$590.69 P/Share
|
|
Dec 02
2025
|
Susan E Burwig Exec. VP, Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+21.05%
|
$1,070,000
$107.93 P/Share
|
|
Dec 02
2025
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
5,698
-0.87%
|
$3,361,820
$590.47 P/Share
|
|
Dec 01
2025
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
23,178
-3.43%
|
$13,744,554
$593.25 P/Share
|
|
Nov 28
2025
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
15,151
-2.19%
|
$8,984,543
$593.46 P/Share
|
|
Nov 26
2025
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
41,331
-5.64%
|
$25,046,586
$606.88 P/Share
|
|
Nov 25
2025
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
42,392
-5.47%
|
$26,071,080
$615.52 P/Share
|
|
Nov 24
2025
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
59,025
-7.08%
|
$35,828,175
$607.78 P/Share
|
|
Nov 24
2025
|
Susan E Burwig Exec. VP, Operations |
SELL
Open market or private sale
|
Direct |
20,000
-42.11%
|
$12,180,000
$609.15 P/Share
|
|
Nov 21
2025
|
Kevin M. Brady CFO & Treasurer |
SELL
Bona fide gift
|
Direct |
170
-2.83%
|
-
|
|
Nov 21
2025
|
Kevin M. Brady CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
3,000
-33.33%
|
$1,770,000
$590.35 P/Share
|
|
Nov 21
2025
|
Kevin M. Brady CFO & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+25.0%
|
$498,000
$166.73 P/Share
|
|
Nov 21
2025
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
21,858
-2.56%
|
$12,939,936
$592.18 P/Share
|
|
Nov 20
2025
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
6,830
-0.79%
|
$4,084,340
$598.49 P/Share
|
|
Nov 19
2025
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
23,862
-2.69%
|
$14,126,304
$592.07 P/Share
|
|
Nov 18
2025
|
August J. Troendle CEO |
SELL
Open market or private sale
|
Direct |
7,191
-0.8%
|
$4,242,690
$590.84 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 527K shares |
|---|---|
| Open market or private purchase | 2 shares |
| Open market or private sale | 562K shares |
|---|---|
| Bona fide gift | 170 shares |